NZE · RUA.NZ · NZD
Stock price, earnings
Quote as of Oct 30, 2026, 01:34 AM UTC. Cached market data; not a live quote.
One-year closing-price history · NZD. Historical prices are not a forecast.
Rua Bioscience Limited’s quoted price sits in the lower half of its reported 52-week range, 38.1% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
BEHIND THE RESULTS
Upcoming dates and analyst estimates may change. Fiscal quarters follow Rua Bioscience Limited’s reporting calendar.
THE COMPANY BEHIND THE TICKER
Rua Bioscience Limited, a company founded in 2016 and headquartered in Gisborne, New Zealand, is dedicated to the investigation, refinement, and production of medicinal products for both the New Zealand market and international distribution. Their offerings primarily include pharmaceuticals developed from cannabinoids. The firm officially changed its name to Rua Bioscience Limited in October 2019, having previously been known as Hikurangi Cannabis Company Limited.
Latest available per-share figures in NZD. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 03:30 PM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
NZ$47.66+NZ$0.28 (+0.59%)
Fisher & Paykel Healthcare Corporation Limited’s quoted price sits in the upper half of its reported 52-week range, 3.97% below the high.
NZ$1.77+NZ$0.03 (+1.72%)
Ryman Healthcare Limited’s quoted price sits in the lower half of its reported 52-week range, 41.97% below the high.
NZ$6.56+NZ$0.06 (+0.92%)
Summerset Group Holdings Limited’s quoted price sits in the lower half of its reported 52-week range, 48.75% below the high.
NZ$4.65-NZ$0.05 (-1.06%)
AFT Pharmaceuticals Limited’s quoted price sits in the upper half of its reported 52-week range, 4.12% below the high.
NZ$0.64-NZ$0.01 (-1.54%)
Oceania Healthcare Limited’s quoted price sits in the lower half of its reported 52-week range, 31.18% below the high.
NZ$0.24NZ$0.00 (0.0%)
Pacific Edge Limited’s quoted price sits in the lower half of its reported 52-week range, 30.88% below the high.
NZ$1.93-NZ$0.01 (-0.26%)
Green Cross Health Limited’s quoted price sits in the upper half of its reported 52-week range, 14.22% below the high.
A$0.55+A$0.02 (+2.8%)
Aroa Biosurgery Limited’s quoted price sits in the lower half of its reported 52-week range, 31.25% below the high.
